NASDAQ:NRIX Nurix Therapeutics Q3 2026 Earnings Results & Report $22.16 -0.19 (-0.85%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$22.16 0.00 (0.00%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nurix Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 13, 2026. The company reported EPS of $4.73 versus the -$0.6009 consensus estimate, while revenue of $673.06 million topped the $24.35 million estimate by $648.72 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET Nurix Therapeutics EPS ResultsActual EPS$4.73Consensus EPS -$0.6009Beat/MissBeat by +$5.3309One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNurix Therapeutics Revenue ResultsActual Revenue$673.06 millionExpected Revenue$24.35 millionBeat/MissBeat by +$648.72 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nurix Therapeutics Q3 2026 Earnings FAQ Did Nurix Therapeutics beat earnings estimates for Q3 2026? Nurix Therapeutics (NASDAQ:NRIX) reported earnings of $4.73 per share for Q3 2026, beating the consensus estimate of -$0.6009. The report was announced on Tuesday, October 13, 2026. What was Nurix Therapeutics' revenue for Q3 2026? Nurix Therapeutics reported revenue of $673.06 million for Q3 2026, against a consensus estimate of $24.35 million. Nurix Therapeutics Earnings HeadlinesNurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateOctober 12 at 4:05 PM | globenewswire.comValion Bio, Inc. Common Stock (NASDAQ:VBIO) & Nurix Therapeutics (NASDAQ:NRIX) Head to Head ComparisonOctober 12 at 4:16 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Nurix Initiates Phase 1b/2 Bexobrutideg Trial In Lymphocytic LeukemiaOctober 7, 2026 | rttnews.comNurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaOctober 7, 2026 | globenewswire.comNurix Therapeutics, Gilead Sciences Agree on Two-Year Research Term Extension for Oncology ProgramOctober 5, 2026 | finance.yahoo.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation. Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology. The company has also developed immune-modulating programs, including therapies intended to activate antitumor immune responses. Founded in 2009, Nurix has advanced its programs through research collaborations and strategic partnerships, including a collaboration with Sanofi focused on targeted protein degradation. The company conducts research and clinical development in the United States and works with international partners and clinical sites as its programs progress. Nurix’s common stock trades on the Nasdaq under the symbol NRIX.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
